a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company’s oncology research strategy.The newfacility will serve as a leading research ...

The new facility will serve as a leading research center for advancing antibody-drug conjugates (ADC) research and development, supporting Boehringer Ingelheim's commitment to developing ...